These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33826790)

  • 1. Clinical evaluation of p16
    Rezhake R; Wang Y; Chen F; Hu SY; Zhang X; Cao J; Qiao YL; Zhao FH; Arbyn M
    Cancer Cytopathol; 2021 Sep; 129(9):679-692. PubMed ID: 33826790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triage options to manage high-risk human papillomavirus-positive women: A population-based cross-sectional study from rural China.
    Rezhake R; Chen F; Hu SY; Zhao XL; Zhang X; Cao J; Qiao YL; Zhao FH; Arbyn M
    Int J Cancer; 2020 Oct; 147(8):2053-2064. PubMed ID: 32249409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical value of p16
    Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
    [No Abstract]   [Full Text] [Related]  

  • 4. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of p16
    Song F; Belinson JL; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    Gynecol Oncol; 2021 Aug; 162(2):322-330. PubMed ID: 34059349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
    Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
    Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
    Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
    BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study.
    White C; Bakhiet S; Bates M; Keegan H; Pilkington L; Ruttle C; Sharp L; O' Toole S; Fitzpatrick M; Flannelly G; O' Leary JJ; Martin CM
    Cytopathology; 2016 Aug; 27(4):269-76. PubMed ID: 26932360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the Performance of p16
    Song F; Du H; Xiao A; Wang C; Huang X; Yan P; Liu Z; Qu X; Belinson JL; Wu R
    Cancer Manag Res; 2020; 12():9067-9075. PubMed ID: 33061601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.
    Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; De Marco L; Giorgi-Rossi P; Pontenani G; Rosso S; Sani C; Sintoni C; Segnan N; Zorzi M; Cuzick J; Rizzolo R; Ronco G;
    Lancet Oncol; 2008 Oct; 9(10):937-45. PubMed ID: 18783988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China.
    Zhang SK; Jia MM; Zhao DM; Wu ZN; Guo Z; Liu YL; Guo PP; Chen Q; Cao XQ; Liu SZ; Chen W; Sun XB
    Cancer Epidemiol; 2019 Apr; 59():123-128. PubMed ID: 30739069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study.
    Wu TJ; Smith-McCune K; Reuschenbach M; von Knebel Doeberitz M; Maloba M; Huchko MJ
    BMJ Open; 2016 Sep; 6(9):e012547. PubMed ID: 27625065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
    Yu LL; Chen W; Lei XQ; Qin Y; Wu ZN; Pan QJ; Zhang X; Chang BF; Zhang SK; Guo HQ; Qiao YL
    Oncotarget; 2016 Apr; 7(16):21181-9. PubMed ID: 27029033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
    Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The triage of low-grade cytological abnormalities by the immunocytological expression of cyclin-dependent kinase inhibitor p16INK4a versus Human Papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+.
    Stănculescu R; Brătilă E; Bauşic V; Vlădescu T
    Rom J Morphol Embryol; 2013; 54(4):1061-5. PubMed ID: 24399002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.
    Reuschenbach M; Clad A; von Knebel Doeberitz C; Wentzensen N; Rahmsdorf J; Schaffrath F; Griesser H; Freudenberg N; von Knebel Doeberitz M
    Gynecol Oncol; 2010 Oct; 119(1):98-105. PubMed ID: 20619445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
    Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G;
    Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
    Wentzensen N; Schwartz L; Zuna RE; Smith K; Mathews C; Gold MA; Allen RA; Zhang R; Dunn ST; Walker JL; Schiffman M
    Clin Cancer Res; 2012 Aug; 18(15):4154-62. PubMed ID: 22675168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.